Skip to main content
Journal cover image

Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.

Publication ,  Journal Article
Sharma, A; Greene, S; Vaduganathan, M; Fudim, M; Ambrosy, AP; Sun, J-L; McNulty, SE; Hernandez, AF; Borlaug, BA; Velazquez, EJ; Mentz, RJ ...
Published in: ESC Heart Fail
August 2021

AIMS: Associations between growth differentiation factor-15 (GDF-15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. We utilized data from the 'Functional Impact of GLP-1 for Heart Failure Treatment' (FIGHT) study to address these knowledge gaps. METHODS AND RESULTS: FIGHT was a randomized clinical trial testing the effect of liraglutide (vs. placebo) among 300 participants with HFrEF and a recent HHF. Multivariable regression models evaluated associations between baseline GDF-15 and change in GDF-15 (per 1000 pg/mL increase from baseline to 30 days) with clinical outcomes (at 180 days) and declines in exercise capacity (6 min walk distance ≥ 45 m). At baseline (n = 249), median GDF-15 value was 3221 pg/mL (interquartile range 1938-5511 pg/mL). Participants in the highest tertile of baseline GDF-15 were more likely to be male and have more co-morbidities. After adjustment, an increase in GDF-15 over 30 days was associated with higher risk of death or HHF [hazard ratio 1.35, 95% confidence interval (CI) 1.11-1.64]. In addition, higher baseline GDF-15 (per 1000 pg/mL until 6000 pg/mL) and an increase in GDF-15 over 30 days were associated with declining 6 min walk distance (odds ratio 1.26, 95% CI 1.02-1.55 and odds ratio 1.37, 95% CI 1.12-1.69, respectively). GDF-15 levels remained stable among participants randomized to liraglutide. CONCLUSIONS: An increase in GDF-15 over 30 days among patients in HFrEF was independently associated with an increased risk of cardiovascular events and declining exercise capacity. These results support the value of longitudinal GDF-15 trajectory in informing risk of heart failure disease progression.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

ESC Heart Fail

DOI

EISSN

2055-5822

Publication Date

August 2021

Volume

8

Issue

4

Start / End Page

2608 / 2616

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Male
  • Liraglutide
  • Humans
  • Heart Failure
  • Growth Differentiation Factor 15
  • Female
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharma, A., Greene, S., Vaduganathan, M., Fudim, M., Ambrosy, A. P., Sun, J.-L., … Felker, G. M. (2021). Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. ESC Heart Fail, 8(4), 2608–2616. https://doi.org/10.1002/ehf2.13348
Sharma, Abhinav, Stephen Greene, Muthiah Vaduganathan, Marat Fudim, Andrew P. Ambrosy, Jie-Lena Sun, Steven E. McNulty, et al. “Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.ESC Heart Fail 8, no. 4 (August 2021): 2608–16. https://doi.org/10.1002/ehf2.13348.
Sharma A, Greene S, Vaduganathan M, Fudim M, Ambrosy AP, Sun J-L, et al. Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. ESC Heart Fail. 2021 Aug;8(4):2608–16.
Sharma, Abhinav, et al. “Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.ESC Heart Fail, vol. 8, no. 4, Aug. 2021, pp. 2608–16. Pubmed, doi:10.1002/ehf2.13348.
Sharma A, Greene S, Vaduganathan M, Fudim M, Ambrosy AP, Sun J-L, McNulty SE, Hernandez AF, Borlaug BA, Velazquez EJ, Mentz RJ, DeVore AD, Alhanti B, Margulies K, Felker GM. Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. ESC Heart Fail. 2021 Aug;8(4):2608–2616.
Journal cover image

Published In

ESC Heart Fail

DOI

EISSN

2055-5822

Publication Date

August 2021

Volume

8

Issue

4

Start / End Page

2608 / 2616

Location

England

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Male
  • Liraglutide
  • Humans
  • Heart Failure
  • Growth Differentiation Factor 15
  • Female
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology